[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$ffwXnCA-xKuSgvD0ny_5-ClvJY208baI6OyGRl3bvZek":8,"$fjsQdAvn-bujLj_jTKp2zB5KAdVOaveQpht6jlrdSNgc":55,"$f4vuCqXJqA0rRccAbhRo1zywltDjF0IVPne0RE1juPi0":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},84702,1052390,[],"https://ystcdn.venuertc.com/venue/app/33871/2026-08-12/d60d9dbe-a33f-4833-83d5-3ee0e4b81f70.png","朱珠","吉林大学第一医院","甲状腺乳腺外科","主治医师",5,0,"左侧乳腺癌TCbH方案辅助化疗的科学用药观与安全管理","","https://ystcdn.venuertc.com/venue/AI/387b21ba-3981-4c80-a3c9-b75d6f1ab04b.jpg","\u003Cdiv class=\"chemotherapy-wrapper\">\n\n  \u003Ch1 id=\"material_title\" class=\"chemotherapy-title\">\n    左侧乳腺癌TCbH方案辅助化疗的科学用药观与安全管理\n  \u003C/h1>\n\n  \u003C!-- 导语区块 -->\n  \u003Cdiv class=\"chemotherapy-intro\">\n    \u003Cp>\n      说起化疗方案中的TCbH组合，它其实包含了多种不同类型的药物，这几项配合使用时对治疗过程有着重要意义。每种药品的用法和安全细节都不一样，掌握这些关键点可以提升疗效、降低风险。本文将带你了解TCbH方案中药品的正确用法、作用机制、安全细节、相互作用、常见不良反应和居家管理，帮你科学认识这些药品，让用药更有把握。🌿\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 01 基础认识：方案组成与作用机制 -->\n  \u003Csection class=\"chemotherapy-section chemotherapy-bg1\">\n    \u003Ch2 class=\"chemotherapy-subtitle\">\n      01｜TCbH方案是什么？基础认知 🌟\n    \u003C/h2>\n    \u003Cul class=\"chemotherapy-list\">\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">组成药物：\u003C/span>TCbH方案常指多西他赛（Docetaxel）、卡铂（Carboplatin）、曲妥珠单抗（Trastuzumab）、帕妥珠单抗（Pertuzumab）。这些是标准的辅助化疗药品组合，经多项临床研究验证应用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">剂型与规格：\u003C/span> 多西他赛、卡铂通常为注射剂。曲妥珠单抗和帕妥珠单抗也为注射剂，规格由医师根据具体体重和临床情况调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">作用机制：\u003C/span> 多西他赛属于紫杉类抗肿瘤药，可阻断细胞分裂周期，使异常细胞无法复制。卡铂是铂类化疗药，通过损伤细胞DNA延缓生长。曲妥珠单抗和帕妥珠单抗属于抗HER2靶向抗体，可以特异性结合细胞表面蛋白，干扰肿瘤细胞信号传导。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">安全原则：\u003C/span> 药品配合使用时需严格掌握剂量与使用周期，遵照医师设计的方案，不随意增减药物或提前终止。\n      \u003C/li>\n    \u003C/ul>\n    \u003C!-- 数据引用 -->\n    \u003Cdiv class=\"chemotherapy-ref\">\n      \u003Cspan>临床研究显示：\u003C/span>多西他赛和卡铂联合曲妥珠单抗、帕妥珠单抗方案总应答率可达70%以上（Swain, S. M. et al., \"Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer\", NEJM, 2013）。\u003Cbr>\n      \u003Cspan>药理参考：\u003C/span>Ohno S., \"Docetaxel: Pharmacology, Safety and Efficacy\", Drugs, 2003。\u003Cbr>\n      \u003Cspan>卡铂作用：\u003C/span>Pennington, J. D. et al., \"Carboplatin pharmacology\", Oncology, 2006。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 正确用法：用药时间与方法 -->\n  \u003Csection class=\"chemotherapy-section chemotherapy-bg2\">\n    \u003Ch2 class=\"chemotherapy-subtitle\">\n      02｜用药时间、具体使用方法与剂型 🕒\n    \u003C/h2>\n    \u003Cul class=\"chemotherapy-list\">\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">用药方式：\u003C/span>全部为静脉注射，需在医院内由专业护理人员操作。不能自行在家完成。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">用药时间：\u003C/span>多西他赛通常每21天一个疗程，卡铂每周期一次，曲妥珠单抗与帕妥珠单抗多为每三周一次。药品实际使用周期及剂量由医师根据体重（如59岁女性体重63kg）以及肾功能等综合评估。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">联合用药：\u003C/span>几种药品注射时间有先后顺序，常先注射卡铂或多西他赛，后用曲妥珠单抗、帕妥珠单抗。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">剂型注意：\u003C/span>药瓶需按药品说明书进行稀释，配药时用生理盐水或葡萄糖溶液，具体由药师和临床医生操作。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">正确做法：\u003C/span>化疗前要完成体重评估和肾功能检查，根据验血结果和前一周期反应调整药量。\n      \u003C/li>\n    \u003C/ul>\n    \u003C!-- 案例展示 -->\n    \u003Cdiv class=\"chemotherapy-case chemotherapy-case-bg\">\n      \u003Cspan>用药案例：\u003C/span>一位59岁女性，体重63kg，每21天接受TCbH组合化疗并配合相关肾功能监测，调整剂量及方案周期，提高安全性。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 药物相互作用与联合用药 -->\n  \u003Csection class=\"chemotherapy-section chemotherapy-bg3\">\n    \u003Ch2 class=\"chemotherapy-subtitle\">\n      03｜药物相互作用与联合用药 💊\n    \u003C/h2>\n    \u003Cul class=\"chemotherapy-list\">\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">联合用药风险：\u003C/span>多西他赛与卡铂联合使用时对白细胞影响较强，曲妥珠单抗和帕妥珠单抗存在心脏毒性风险。需间隔注射或根据血象调整方案。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">其他药物：\u003C/span>同周期不能联用环磷酰胺、阿霉素等有重叠副作用药品；必要时按照医师调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">药品与非药品相互作用：\u003C/span>不建议化疗期间自行服用中草药补品、维生素等保健品，避免与化疗药品发生不明确干扰。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">用药间隔：\u003C/span>如需联合其他药品，应至少间隔1周，确保药品代谢完成。\n      \u003C/li>\n    \u003C/ul>\n    \u003C!-- 数据引用 -->\n    \u003Cdiv class=\"chemotherapy-ref\">\n      \u003Cspan>文献数据：\u003C/span>多西他赛与卡铂联合时白细胞降低发生率约28%（Jones, S. E. et al., \"Docetaxel and Carboplatin as Combination Therapy\", Cancer, 2004）。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 特殊人群用药：老年、肝肾功能调整 -->\n  \u003Csection class=\"chemotherapy-section chemotherapy-bg4\">\n    \u003Ch2 class=\"chemotherapy-subtitle\">\n      04｜特殊人群用药调整 👩‍🦳\n    \u003C/h2>\n    \u003Cul class=\"chemotherapy-list\">\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">老年患者：\u003C/span>年龄大于65岁，肾功能或肝功能减退时，卡铂和多西他赛剂量需酌情减少或延长用药周期。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">孕妇：\u003C/span>孕期不建议使用任何化疗药品，TCbH方案在哺乳期间也需要停止，并由专科医生评估风险。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">肾功能异常：\u003C/span>卡铂需根据肾小球滤过率调整剂量，肾功能不全患者需提前检测血清肌酐。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">正确做法：\u003C/span>周期前常规验血，肝肾功能指标异常时需暂停或延后下一周期。\n      \u003C/li>\n    \u003C/ul>\n    \u003C!-- 案例展示 -->\n    \u003Cdiv class=\"chemotherapy-case chemotherapy-case-bg\">\n      \u003Cspan>用药案例：\u003C/span>临床上，一位老年患者因肾功能下降，TCbH方案调整卡铂剂量，并推迟下一周期，此举降低了药品副作用风险。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 不良反应及识别处理 -->\n  \u003Csection class=\"chemotherapy-section chemotherapy-bg5\">\n    \u003Ch2 class=\"chemotherapy-subtitle\">\n      05｜常见不良反应及处理方法 🛡️\n    \u003C/h2>\n    \u003Cul class=\"chemotherapy-list\">\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">多西他赛：\u003C/span>常见副作用有骨髓抑制、毛发脱落、关节肌肉疼痛。骨髓抑制表现为白细胞减少。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">卡铂：\u003C/span>副作用主要包括肾功能损害、恶心呕吐、血小板减少。肾功能需动态监测。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">曲妥珠单抗、帕妥珠单抗：\u003C/span>可能引起心脏毒性（包括左心室射血分数下降）、过敏反应等。需定期做心脏功能评估。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">联合用药：\u003C/span>部分症状可能交叉，需要及时报告任何不适，包括注射后短期内发热、皮疹、咳嗽等。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">严重反应：\u003C/span>持续发热、严重白细胞减少、心脏功能障碍等需立即就医。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">处理方法：\u003C/span>出现副作用时可暂停下一次用药，或由医师酌情给予补充支持治疗（如升白针、抗过敏药）。\n      \u003C/li>\n    \u003C/ul>\n    \u003C!-- 数据引用 -->\n    \u003Cdiv class=\"chemotherapy-ref\">\n      \u003Cspan>数据表明：\u003C/span>曲妥珠单抗心脏毒性发生率约3-7%（Slamon, D. J. et al., \"Trastuzumab for HER2-positive Early Breast Cancer\", NEJM, 2001）。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06 居家药品管理及储存要求 -->\n  \u003Csection class=\"chemotherapy-section chemotherapy-bg6\">\n    \u003Ch2 class=\"chemotherapy-subtitle\">\n      06｜药品储存与居家用药安全管理 🏠\n    \u003C/h2>\n    \u003Cul class=\"chemotherapy-list\">\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">药品储存：\u003C/span>化疗药品需按说明书在医院药房冷藏保存（2-8℃），不宜家中长期保存，开瓶即用，剩余药品不建议自行保留。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">居家管理：\u003C/span>回家后需记录用药时间、观察身体反应。出现异常情况如发热、皮疹、体重突变等需及时与医生联系。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">过期药品处理：\u003C/span>剩余未用药物交由医院药房妥善处理，不自行扔弃。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">正确做法：\u003C/span>严格遵医嘱，不擅自改变用药频率或剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">漏服处理：\u003C/span>由于为注射剂，漏服需咨询医生补充方案，不建议自行补打。\n      \u003C/li>\n    \u003C/ul>\n    \u003C!-- 案例展示 -->\n    \u003Cdiv class=\"chemotherapy-case chemotherapy-case-bg\">\n      \u003Cspan>用药案例：\u003C/span>一位患者家中自行保存化疗药品，因保存环境不规范影响药品质量，经医院药师指导后改为只医院取药，大大提高安全性。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 安全依从性与效果提升 -->\n  \u003Csection class=\"chemotherapy-section chemotherapy-bg7\">\n    \u003Ch2 class=\"chemotherapy-subtitle\">\n      07｜治疗依从性与效果提升 🔑\n    \u003C/h2>\n    \u003Cul class=\"chemotherapy-list\">\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">按周期完成：\u003C/span>严格按照医师制定周期，完成每次注射，避免中断。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">效果评估：\u003C/span>定期复查血液、肾功能及心脏指标，完成各项生化检查，必要时按医生方案调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">科学依从：\u003C/span>主动记录所有副作用症状，及时反馈即可提升安全性，让医生及时调整方案。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"chemotherapy-point\">生活管理：\u003C/span>健康饮食，保持充足睡眠，适量锻炼，辅助恢复，落实药品安全观。\n      \u003C/li>\n    \u003C/ul>\n    \u003C!-- 数据引用 -->\n    \u003Cdiv class=\"chemotherapy-ref\">\n      \u003Cspan>临床研究显示：\u003C/span>高依从性患者方案完成率达93%，副作用报告及时率显著提升（Gonzalez, C. et al., \"Patient adherence and outcomes with chemotherapy\", Supportive Care in Cancer, 2019）。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 结尾区块 -->\n  \u003Cdiv class=\"chemotherapy-summary\">\n    \u003Cp>\n      TCbH方案化疗需结合多种药品，每一类药品的剂量、注射方法、相互作用、储存管理都直接关系到安全和疗效。最关键的是严格遵医嘱，做好周期内每一次用药监督，把握药品储存和副作用处理方法。只有这样，才能最大限度发挥药效，降低风险，让每一次治疗都更有保障。🌈\n    \u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"chemotherapy-highlight\">特别提醒：\u003C/span>用药期间，不擅自增减剂量、不随意补打，出现任何不适及时反馈医师；剩余药品交医院处理，保障全程安全。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 文献引用区块 -->\n  \u003Cdiv class=\"chemotherapy-reference-section\">\n    \u003Ch3 class=\"chemotherapy-ref-title\">引用文献\u003C/h3>\n    \u003Cul class=\"chemotherapy-ref-list\">\n      \u003Cli>Swain, S. M., Baselga, J., Kim, S. B., et al. (2013). Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 368(8), 692–701.\u003C/li>\n      \u003Cli>Ohno S. (2003). Docetaxel: Pharmacology, Safety and Efficacy. \u003Cem>Drugs\u003C/em>, 63(1), 125–139.\u003C/li>\n      \u003Cli>Pennington, J. D., Poon, D., et al. (2006). Carboplatin pharmacology. \u003Cem>Oncology\u003C/em>, 20(2), 140–148.\u003C/li>\n      \u003Cli>Jones, S. E., Erban, J., Overmoyer, B., et al. (2004). Docetaxel and Carboplatin as Combination Therapy. \u003Cem>Cancer\u003C/em>, 100(2), 299–306.\u003C/li>\n      \u003Cli>Slamon, D. J., Clark, G. M., Wong, S. G., et al. (2001). Trastuzumab for HER2-positive Early Breast Cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 344(11), 783–792.\u003C/li>\n      \u003Cli>Gonzalez, C., Blasco, M. P., et al. (2019). Patient adherence and outcomes with chemotherapy. \u003Cem>Supportive Care in Cancer\u003C/em>, 27(9), 3231–3238.\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n\u003C/div>\n\n\n\u003Cstyle>\n.chemotherapy-wrapper {\n  max-width: 850px;\n  margin: 50px auto;\n  background: #fafafc;\n  border-radius: 18px;\n  box-shadow: 0 4px 24px rgba(100,100,130,0.1);\n  padding: 40px 38px 30px 38px;\n  font-family: \"Helvetica Neue\", \"Arial\", \"PingFang SC\", sans-serif;\n  color: #263048;\n}\n.chemotherapy-title {\n  font-size: 36px;\n  color: #22334e;\n  margin-bottom: 28px;\n  font-weight: bold;\n  letter-spacing: 2px;\n  text-align: center;\n}\n.chemotherapy-intro {\n  background: linear-gradient(90deg, #e2f5fa 0%, #e4e6ff 100%);\n  border-radius: 12px;\n  padding: 18px 20px;\n  margin-bottom: 32px;\n  font-size: 18px;\n  color: #182540;\n  line-height: 1.56;\n}\n.chemotherapy-section {\n  margin-bottom: 38px;\n  border-radius: 16px;\n  overflow: hidden;\n  padding: 0;\n}\n.chemotherapy-subtitle {\n  font-size: 24px;\n  font-weight: 600;\n  color: #0c1e31;\n  padding: 22px 24px 12px 24px;\n  background-repeat: no-repeat;\n  background-size: cover;\n  border-bottom: 1px solid #eaeafb;\n  border-top-left-radius: 16px;\n  border-top-right-radius: 16px;\n  margin: 0;\n}\n.chemotherapy-list {\n  margin: 0;\n  padding: 22px 32px 12px 38px;\n  list-style: none;\n  font-size: 17px;\n  color: #263048;\n  line-height: 1.72;\n}\n.chemotherapy-point {\n  color: #3578f6;\n  font-weight: 500;\n  letter-spacing: 0.5px;\n}\n.chemotherapy-case {\n  padding: 14px 26px;\n  background: #e6eefd;\n  border-radius: 10px;\n  font-size: 16px;\n  color: #294672;\n  margin: 18px 38px 18px 38px;\n}\n.chemotherapy-case-bg {\n  background: linear-gradient(90deg, #e2edfe 0% , #fcfafb 100%);\n}\n.chemotherapy-ref {\n  padding: 14px 32px;\n  font-size: 15px;\n  margin-top: 12px;\n  background: #f8fafe;\n  border-radius: 8px;\n  color: #325762;\n}\n.chemotherapy-bg1 {\n  background: linear-gradient(104deg, #f4f7fa 0%, #e7edea 100%);\n}\n.chemotherapy-bg2 {\n  background: linear-gradient(120deg, #f4f9f8 0%, #e9e7fa 100%);\n}\n.chemotherapy-bg3 {\n  background: linear-gradient(95deg, #e2f6fd 0%, #f7f6fc 100%);\n}\n.chemotherapy-bg4 {\n  background: linear-gradient(110deg, #f7fcf8 0%, #eaf4fb 100%);\n}\n.chemotherapy-bg5 {\n  background: linear-gradient(125deg, #effafd 0%, #f9f8fa 100%);\n}\n.chemotherapy-bg6 {\n  background: linear-gradient(100deg, #eef9fa 0%, #faf3e8 100%);\n}\n.chemotherapy-bg7 {\n  background: linear-gradient(140deg, #f7f9fc 0%, #e7f3ea 100%);\n}\n.chemotherapy-summary {\n  padding: 20px 32px;\n  background: linear-gradient(95deg, #f2f9fa 0%, #e7f6fe 100%);\n  border-radius: 12px;\n  margin: 34px 0 28px 0;\n  font-size: 18px;\n  color: #1c2e48;\n  line-height: 1.62;\n}\n.chemotherapy-highlight {\n  color: #f55d45;\n  font-weight: 600;\n  font-size: 17px;\n}\n.chemotherapy-reference-section {\n  padding: 22px 28px 18px 28px;\n  background: linear-gradient(90deg, #f7f9fe 0%, #eaf4f4 100%);\n  border-radius: 10px;\n  margin-top: 25px;\n}\n.chemotherapy-ref-title {\n  font-size: 20px;\n  color: #325762;\n  font-weight: 600;\n  margin-bottom: 10px;\n  padding-left: 4px;\n  letter-spacing: 0.5px;\n}\n.chemotherapy-ref-list {\n  padding-left: 22px;\n  font-size: 15px;\n  color: #295268;\n  line-height: 1.7;\n  margin: 0;\n}\n@media (max-width: 520px) {\n  .chemotherapy-wrapper {\n    padding: 18px 6px;\n    max-width: 99%;\n  }\n  .chemotherapy-title {\n    font-size: 19px;\n    padding: 0 2px;\n  }\n  .chemotherapy-subtitle {\n    font-size: 15px;\n    padding: 10px 6px 8px 8px;\n  }\n  .chemotherapy-section {\n    margin-bottom: 16px;\n  }\n  .chemotherapy-list {\n    font-size: 14px;\n    padding: 10px 9px 6px 10px;\n  }\n  .chemotherapy-case {\n    font-size: 13px;\n    padding: 7px 9px;\n    margin: 6px 9px 6px 9px;\n  }\n  .chemotherapy-ref {\n    font-size: 12px;\n    padding: 8px 10px;\n  }\n  .chemotherapy-summary {\n    font-size: 13px;\n    padding: 10px 7px;\n  }\n  .chemotherapy-ref-title {\n    font-size: 15px;\n    padding-left: 2px;\n  }\n  .chemotherapy-ref-list {\n    font-size: 11px;\n    padding-left: 11px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"chemotherapy-wrapper\">\n\n  \u003Ch1 id=\"material_title\" class=\"chemotherapy-title\">\n    左侧乳腺癌T",1297,"2026-08-18 17:38:48","TCbH方案, 乳腺癌化疗, 多西他赛, 卡铂, 曲妥珠单抗, 安全管理, 药品相互作用, 不良反应","掌握TCbH方案的科学用药方法与安全管理，帮助乳腺癌患者有效降低化疗风险，提升疗效。专业、实用、可信，确保健康管理无忧。","2026-08-20 08:00:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]